Inhibrx Biosciences, Inc. INBX Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s accrued liabilities, current?
- Inhibrx Biosciences, Inc. (INBX) reported accrued liabilities, current of $15.34M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s accrued liabilities, current changed year-over-year?
- Inhibrx Biosciences, Inc.'s accrued liabilities, current decreased by 53.2% year-over-year, from $32.77M to $15.34M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s accrued liabilities, current?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s accrued liabilities, current has grown at a -23.2% compound annual growth rate (CAGR), from $43.3M to $25.53M.